KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash & Equivalents (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Cash & Equivalents for 16 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 40.97% year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Sep 2025, up 40.97%, and an annual FY2024 reading of $5.1 million, up 16.92% over the prior year.
  • Cash & Equivalents was $7.1 million for Q3 2025 at TherapeuticsMD, up from $6.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $137.6 million in Q1 2021 and bottomed at $4.3 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $34.7 million, with a median of $13.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 91.23% in 2023, then soared 40.97% in 2025.
  • Year by year, Cash & Equivalents stood at $64.9 million in 2021, then decreased by 24.02% to $49.3 million in 2022, then crashed by 91.23% to $4.3 million in 2023, then rose by 16.92% to $5.1 million in 2024, then skyrocketed by 40.64% to $7.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for TXMD at $7.1 million in Q3 2025, $6.1 million in Q2 2025, and $5.7 million in Q1 2025.